10/28/11 Contest Update
Is the Greek debt deal a Trojan Horse or a true thoroughbred of German-French pedigree? So far, investors have bet big on the latter. But with the race far from over, prematurely banking on the outcome entails significant risk.
At Friday’s close, the NBI was up 7.45% YTD (vs. up 4.24% YTD a week ago) and the Contest median was up 1.07% YTD (vs. down -3.07% YTD a week ago). The Nasdaq Composite Index was up 3.18% YTD (vs. down -.58% YTD a week ago).
JIBAC’s portfolio (up 59.12% YTD) had another terrific week and further widened its lead, with GENE’s portfolio (up 41.66% YTD) holding on to second place and ROCKY’s portfolio (up 41.01% YTD) slipping into third place.
At Friday's close, 20 of the 38 Contest portfolios were in the black, while 11 were beating the NBI.
Below is the Top Ten list. Also below are the Top 5 & Bottom 5 Stocks ranked by % Gained and % Lost for the week (foreign stock prices are not converted to US$ in these two tables).
Portfolio adjustments: None
Have a wonderful weekend biotechies!
(All corrections, especially adjustments for splits, greatly appreciated.)
10/28/11
Rank Name Profit/Loss
1 JIBAC 59,122
2 GENE 41,664
3 ROCKY 41,007
4 FIB 39,557
5 MCBIO 38,240
6 RRGE 35,584
7 IJF 17,278
8 BIOFISH 16,416
9 JULIUS 15,634
10 WILDER 10,946
Week's Top 5 Gainers
Symbol 10/21 10/28 % change
AOB 0.57 0.77 35.11%
EXEL 5.99 7.60 26.88%
ZLCS 1.01 1.27 25.74%
ZIOP 4.19 5.15 22.91%
BSTC 15.58 19.08 22.43%
Week's Top 5 Losers
Symbol 10/21 10/28 % change
NRGX.OB 0.52 0.44 -15.38%
ROSG 0.82 0.72 -11.93%
VASC 12.19 10.81 -11.32%
MRNA 0.19 0.17 -11.23%
REGN 62.17 55.66 -10.47% |
